CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: antibody drugs</title> <meta name="description" content="Search results for: antibody drugs"> <meta name="keywords" content="antibody drugs"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="antibody drugs" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="antibody drugs"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 1450</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: antibody drugs</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1450</span> 'Antibody Exception' under Dispute and Waning Usage: Potential Influence on Patenting Antibodies</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Xiangjun%20Kong">Xiangjun Kong</a>, <a href="https://publications.waset.org/abstracts/search?q=Dongning%20Yao"> Dongning Yao</a>, <a href="https://publications.waset.org/abstracts/search?q=Yuanjia%20Hu"> Yuanjia Hu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Therapeutic antibodies have become the most valuable and successful class of biopharmaceutical drugs, with a huge market potential and therapeutic advantages. Antibody patents are, accordingly, extremely important. As the technological limitation of the early stage of this field, the U. S. Patent and Trademark Offices (USPTO) have issued guidelines that suggest an exception for patents claiming a genus of antibodies that bind to a novel antigen, even in the absence of any experimental antibody production. This 'antibody exception' allowed for a broad scope on antibody claims, and led a global trend to patent antibodies without antibodies. Disputes around the pertinent patentability and written description issues remain particularly intense. Yet the validity of such patents had not been overtly challenged until Centocor v. Abbott, which restricted the broad scope of antibody patents and hit the brakes on the 'antibody exception'. The courts tend to uphold the requirement for adequate description of antibodies in the patent specifications, to avoid overreaching antibody claims. Patents following the 'antibody exception' are at risk of being found invalid for inadequately describing what they have claimed. However, the relation between the court and USPTO guidelines remains obscure, and the waning of the 'antibody exception' has led to further disputes around antibody patents. This uncertainty clearly affects patent applications, antibody innovations, and even relevant business performance. This study will give an overview of the emergence, debate, and waning usage of the 'antibody exception' in a number of enlightening cases, attempting to understand the specific concerns and the potential influence of antibody patents. We will then provide some possible strategies for antibody patenting, under the current considerations on the 'antibody exception'. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=antibody%20exception" title="antibody exception">antibody exception</a>, <a href="https://publications.waset.org/abstracts/search?q=antibody%20patent" title=" antibody patent"> antibody patent</a>, <a href="https://publications.waset.org/abstracts/search?q=USPTO%20%28U.%20S.%20Patent%20and%20Trademark%20Offices%29%20guidelines" title=" USPTO (U. S. Patent and Trademark Offices) guidelines"> USPTO (U. S. Patent and Trademark Offices) guidelines</a>, <a href="https://publications.waset.org/abstracts/search?q=written%20description%20requirement" title=" written description requirement"> written description requirement</a> </p> <a href="https://publications.waset.org/abstracts/93426/antibody-exception-under-dispute-and-waning-usage-potential-influence-on-patenting-antibodies" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/93426.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">159</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1449</span> Quality Based Approach for Efficient Biologics Manufacturing</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Takashi%20Kaminagayoshi">Takashi Kaminagayoshi</a>, <a href="https://publications.waset.org/abstracts/search?q=Shigeyuki%20Haruyama"> Shigeyuki Haruyama</a> </p> <p class="card-text"><strong>Abstract:</strong></p> To improve the manufacturing efficiency of biologics, such as antibody drugs, a quality engineering framework was designed. Within this framework, critical steps and parameters in the manufacturing process were studied. Identification of these critical steps and critical parameters allows a deeper understanding of manufacturing capabilities, and suggests to process development department process control standards based on actual manufacturing capabilities as part of a PDCA (plan-do-check-act) cycle. This cycle can be applied to each manufacturing process so that it can be standardized, reducing the time needed to establish each new process. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=antibody%20drugs" title="antibody drugs">antibody drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=biologics" title=" biologics"> biologics</a>, <a href="https://publications.waset.org/abstracts/search?q=manufacturing%20efficiency" title=" manufacturing efficiency"> manufacturing efficiency</a>, <a href="https://publications.waset.org/abstracts/search?q=PDCA%20cycle" title=" PDCA cycle"> PDCA cycle</a>, <a href="https://publications.waset.org/abstracts/search?q=quality%20engineering" title=" quality engineering"> quality engineering</a> </p> <a href="https://publications.waset.org/abstracts/42626/quality-based-approach-for-efficient-biologics-manufacturing" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/42626.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">345</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1448</span> Monitoring of Humoral Immune Response of Monovalent and Combined PPR and FMD Serotype 'O' Virus Vaccines in Goats</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mudassar%20Hameed">Mudassar Hameed</a>, <a href="https://publications.waset.org/abstracts/search?q=Khushi%20Muhammad"> Khushi Muhammad</a>, <a href="https://publications.waset.org/abstracts/search?q=Aamir%20Ghafoor"> Aamir Ghafoor</a>, <a href="https://publications.waset.org/abstracts/search?q=Masood%20%20Rabbani"> Masood Rabbani</a>, <a href="https://publications.waset.org/abstracts/search?q=Momena%20Habib"> Momena Habib</a>, <a href="https://publications.waset.org/abstracts/search?q=Jawad%20Nazir"> Jawad Nazir</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Comparative efficacy of three formulations (non-adjuvant, gel, and oil adjuvant) of monovalent and combined PPR and FMD virus vaccines was evaluated in goats. All kinds of monovalent PPRV vaccines elicited protective antibody titers at one-month post vaccination (PV) that remained so till six months PV. Monovalent non-adjuvant (NA) FMDV vaccine provoked non-protective antibody titers that declined to undetectable levels after three months. In case of combined vaccines, all of the formulations elicited protective antibody titers against PPRV in vaccinated animals which remained above that limit for six months. However, an exceptional immune response against FMDV was observed in combined NA vaccine group where antibody titers were extremely high and remained above protective level till 4 months PV in animals who received a single vaccine shot and till six months PV in booster group. Although, adjuvant or NA combined vaccines can induce protective antibody titers against both of the viruses within one month PV, but a booster vaccine shot is needed to retain protective antibody level for 6 months duration. Immune response elicited by combined vaccines is comparable or superior to the monovalent vaccines. Hence combined vaccine can be effectively used for the control and prevention of both of the diseases. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=antibody%20titer" title="antibody titer">antibody titer</a>, <a href="https://publications.waset.org/abstracts/search?q=protective" title=" protective"> protective</a>, <a href="https://publications.waset.org/abstracts/search?q=combined%20vaccine" title=" combined vaccine"> combined vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=non%20adjuvant" title=" non adjuvant"> non adjuvant</a> </p> <a href="https://publications.waset.org/abstracts/83674/monitoring-of-humoral-immune-response-of-monovalent-and-combined-ppr-and-fmd-serotype-o-virus-vaccines-in-goats" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/83674.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">204</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1447</span> Targeted Nano Anti-Cancer Drugs for Curing Cancers</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Imran%20Ali">Imran Ali</a> </p> <p class="card-text"><strong>Abstract:</strong></p> General chemotherapy for cancer treatment has many side and toxic effects. A new approach of targeting nano anti-cancer drug is under development stage and only few drugs are available in the market today. The unique features of these drugs are targeted action on cancer cells only without any side effect. Sometimes, these are called magic drugs. The important molecules used for nano anti-cancer drugs are cisplatin, carboplatin, bleomycin, 5-fluorouracil, doxorubicin, dactinomycin, 6-mercaptopurine, paclitaxel, topotecan, vinblastin and etoposide etc. The most commonly used materials for preparing nano particles carriers are dendrimers, polymeric, liposomal, micelles inorganic, organic etc. The proposed lecture will comprise the-of-art of nano drugs in cancer chemo-therapy including preparation, types of drugs, mechanism, future perspectives etc. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer" title="cancer">cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=nano-anti-cancer%20drugs" title=" nano-anti-cancer drugs"> nano-anti-cancer drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=chemo-therapy" title=" chemo-therapy"> chemo-therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=mechanism%20of%20action" title=" mechanism of action"> mechanism of action</a>, <a href="https://publications.waset.org/abstracts/search?q=future%20perspectives" title=" future perspectives"> future perspectives</a> </p> <a href="https://publications.waset.org/abstracts/32360/targeted-nano-anti-cancer-drugs-for-curing-cancers" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/32360.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">448</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1446</span> Detection of Heroin and Its Metabolites in Urine Samples: A Chemiluminescence Approach</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sonu%20Gandhi">Sonu Gandhi</a>, <a href="https://publications.waset.org/abstracts/search?q=Neena%20Capalash"> Neena Capalash</a>, <a href="https://publications.waset.org/abstracts/search?q=Prince%20Sharma"> Prince Sharma</a>, <a href="https://publications.waset.org/abstracts/search?q=C.%20Raman%20Suri"> C. Raman Suri</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A sensitive chemiluminescence immunoassay (CIA) for heroin and its major metabolites is reported. The method is based on the competitive reaction of horseradish peroxidase (HRP)-labeled anti-MAM antibody and free drug in spiked urine samples. A hapten-protein conjugate was synthesized by using acidic derivative of monoacetyl morphine (MAM) coupled to carrier protein BSA and was used as an immunogen for the generation of anti-MAM (monoacetyl morphine) antibody. A high titer of antibody (1:64,0000) was obtained and the relative affinity constant (Kaff) of antibody was 3.1×107 l/mol. Under the optimal conditions, linear range and reactivity for heroin, mono acetyl morphine (MAM), morphine and codeine were 0.08, 0.09, 0.095 and 0.092 ng/mL respectively. The developed chemiluminescence inhibition assay could detect heroin and its metabolites in standard and urine samples up to 0.01 ng/ml. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=heroin" title="heroin">heroin</a>, <a href="https://publications.waset.org/abstracts/search?q=metabolites" title=" metabolites"> metabolites</a>, <a href="https://publications.waset.org/abstracts/search?q=chemiluminescence%20immunoassay" title=" chemiluminescence immunoassay"> chemiluminescence immunoassay</a>, <a href="https://publications.waset.org/abstracts/search?q=horse%20radish%20peroxidase" title=" horse radish peroxidase "> horse radish peroxidase </a> </p> <a href="https://publications.waset.org/abstracts/44063/detection-of-heroin-and-its-metabolites-in-urine-samples-a-chemiluminescence-approach" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/44063.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">270</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1445</span> Health Hazards of Performance Enhancing Drugs</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Austin%20Oduor%20Otieno">Austin Oduor Otieno</a> </p> <p class="card-text"><strong>Abstract:</strong></p> There is an ingrained belief that the use of performance-enhancing drugs by athletes enable them to perform better. While this has been found to be truth, it also raises ethical and health issues. This paper analyzes the health hazards associated with performance enhancing drugs. It seeks to achieve this through the analysis of different academic journals as well as publications on the relationship between doping in sports and health. It concludes that there are inherent health hazards associated with the use of performance-enhancing drugs as they affect the physical and psychological health and wellbeing of a user (athlete). <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=doping" title="doping">doping</a>, <a href="https://publications.waset.org/abstracts/search?q=health%20hazards" title=" health hazards"> health hazards</a>, <a href="https://publications.waset.org/abstracts/search?q=athletes" title=" athletes"> athletes</a>, <a href="https://publications.waset.org/abstracts/search?q=drugs" title=" drugs"> drugs</a> </p> <a href="https://publications.waset.org/abstracts/135349/health-hazards-of-performance-enhancing-drugs" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/135349.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">164</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1444</span> Antibody-Conjugated Nontoxic Arginine-Doped Fe3O4 Nanoparticles for Magnetic Circulating Tumor Cells Separation</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=F.%20Kashanian">F. Kashanian</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20M.%20Masoudi"> M. M. Masoudi</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Akbari"> A. Akbari</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Shamloo"> A. Shamloo</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20R.%20Zand"> M. R. Zand</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20S.%20Salehi"> S. S. Salehi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Nano-sized materials present new opportunities in biology and medicine and they are used as biomedical tools for investigation, separation of molecules and cells. To achieve more effective cancer therapy, it is essential to select cancer cells exactly. This research suggests that using the antibody-functionalized nontoxic Arginine-doped magnetic nanoparticles (A-MNPs), has been prosperous in detection, capture, and magnetic separation of circulating tumor cells (CTCs) in tumor tissue. In this study, A-MNPs were synthesized via a simple precipitation reaction and directly immobilized Ep-CAM EBA-1 antibodies over superparamagnetic A-MNPs for Mucin BCA-225 in breast cancer cell. The samples were characterized by vibrating sample magnetometer (VSM), FT-IR spectroscopy, Tunneling Electron Microscopy (TEM) and Scanning Electron Microscopy (SEM). These antibody-functionalized nontoxic A-MNPs were used to capture breast cancer cell. Through employing a strong permanent magnet, the magnetic separation was achieved within a few seconds. Antibody-Conjugated nontoxic Arginine-doped Fe<sub>3</sub>O<sub>4</sub> nanoparticles have the potential for the future study to capture CTCs which are released from tumor tissue and for drug delivery, and these results demonstrate that the antibody-conjugated A-MNPs can be used in magnetic hyperthermia techniques for cancer treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=tumor%20tissue" title="tumor tissue">tumor tissue</a>, <a href="https://publications.waset.org/abstracts/search?q=antibody" title=" antibody"> antibody</a>, <a href="https://publications.waset.org/abstracts/search?q=magnetic%20nanoparticle" title=" magnetic nanoparticle"> magnetic nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=CTCs%20capturing" title=" CTCs capturing"> CTCs capturing</a> </p> <a href="https://publications.waset.org/abstracts/67417/antibody-conjugated-nontoxic-arginine-doped-fe3o4-nanoparticles-for-magnetic-circulating-tumor-cells-separation" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/67417.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">360</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1443</span> ELISA Based hTSH Assessment Using Two Sensitive and Specific Anti-hTSH Polyclonal Antibodies</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Maysam%20Mard-Soltani">Maysam Mard-Soltani</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamad%20Javad%20Rasaee"> Mohamad Javad Rasaee</a>, <a href="https://publications.waset.org/abstracts/search?q=Saeed%20Khalili"> Saeed Khalili</a>, <a href="https://publications.waset.org/abstracts/search?q=Abdol%20Karim%20Sheikhi"> Abdol Karim Sheikhi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehdi%20Hedayati"> Mehdi Hedayati</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Production of specific antibody responses against hTSH is a cumbersome process due to the high identity between the hTSH and the other members of the glycoprotein hormone family (FSH, LH and HCG) and the high identity between the human hTSH and host animals for antibody production. Therefore, two polyclonal antibodies were purified against two recombinant proteins. Four possible ELISA tests were designed based on these antibodies. These ELISA tests were checked against hTSH and other glycoprotein hormones, and their sensitivity and specificity were assessed. Bioinformatics tools were used to analyze the immunological properties. After the immunogen region selection from hTSH protein, c terminal of B hTSH was selected and applied. Two recombinant genes, with these cut pieces (first: two repeats of C terminal of B hTSH, second: tetanous toxin+B hTSH C terminal), were designed and sub-cloned into the pET32a expression vector. Standard methods were used for protein expression, purification, and verification. Thereafter, immunizations of the white New Zealand rabbits were performed and the serums of them were used for antibody titration, purification and characterization. Then, four ELISA tests based on two antibodies were employed to assess the hTSH and other glycoprotein hormones. The results of these assessments were compared with standard amounts. The obtained results indicated that the desired antigens were successfully designed, sub-cloned, expressed, confirmed and used for <em>in vivo</em> immunization. The raised antibodies were capable of specific and sensitive hTSH detection, while the cross reactivity with the other members of the glycoprotein hormone family was minimum. Among the four designed tests, the test in which the antibody against first protein was used as capture antibody, and the antibody against second protein was used as detector antibody did not show any hook effect up to 50 miu/l. Both proteins have the ability to induce highly sensitive and specific antibody responses against the hTSH. One of the antibody combinations of these antibodies has the highest sensitivity and specificity in hTSH detection. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hTSH" title="hTSH">hTSH</a>, <a href="https://publications.waset.org/abstracts/search?q=bioinformatics" title=" bioinformatics"> bioinformatics</a>, <a href="https://publications.waset.org/abstracts/search?q=protein%20expression" title=" protein expression"> protein expression</a>, <a href="https://publications.waset.org/abstracts/search?q=cross%20reactivity" title=" cross reactivity"> cross reactivity</a> </p> <a href="https://publications.waset.org/abstracts/84047/elisa-based-htsh-assessment-using-two-sensitive-and-specific-anti-htsh-polyclonal-antibodies" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/84047.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">189</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1442</span> Comparison of the Use of Vaccines or Drugs against Parasitic Diseases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Al-Khalaifa">H. Al-Khalaifa</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Al-Nasser"> A. Al-Nasser</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The viewpoint towards the use of drugs or vaccines against avian parasitic diseases is one of the most striking challenges in avian medical parasitology. This includes many difficulties associated with drug resistance and in developing prophylactic vaccines. In many instances, the potential success of a vaccination in controlling parasitic diseases in poultry is well-documented. However, some medical, technical and financial limitations are still paramount. On the other hand, chemotherapy is not very well-recommended due to a number of medical limitations. But in the absence of an effective vaccine, drugs are used against parasitic diseases. This paper sheds light on some the advantages and disadvantages of using vaccination and drugs in controlling parasitic diseases in poultry species. The usage of chemotherapeutic drugs is discussed with some examples. Then, more light will be shed on using vaccines as a potentially effective and promising control tool. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=drugs" title="drugs">drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=parasitology" title=" parasitology"> parasitology</a>, <a href="https://publications.waset.org/abstracts/search?q=poultry" title=" poultry"> poultry</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccines" title=" vaccines"> vaccines</a> </p> <a href="https://publications.waset.org/abstracts/85588/comparison-of-the-use-of-vaccines-or-drugs-against-parasitic-diseases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/85588.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">208</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1441</span> Drugs, Silk Road, Bitcoins</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Lali%20Khurtsia">Lali Khurtsia</a>, <a href="https://publications.waset.org/abstracts/search?q=Vano%20Tsertsvadze"> Vano Tsertsvadze</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Georgian drug policy is directed to reduce the supply of drugs. Retrospective analysis has shown that law enforcement activities have been followed by the expulsion of particular injecting drugs. The demand remains unchanged and drugs are substituted by the hand-made, even more dangerous homemade drugs entered the market. To find out expected new trends on the Georgian drug market, qualitative study was conducted with Georgian drug users to determine drug supply routes. It turned out that drug suppliers and consumers for safety reasons and to protect their anonymity, use Skype to make deals. IT in illegal drug trade is even more sophisticated in the worldwide. Trading with Bitcoins in the Darknet ensures high confidentiality of money transactions and the safe circulation of drugs. In 2014 largest Bitcoin mining enterprise in the world was built in Georgia. We argue that the use of Bitcoins and Darknet by Georgian drug consumers and suppliers will be an incentive to response adequately to the government's policy of restricting supply in order to satisfy market demand for drugs. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bitcoin" title="bitcoin">bitcoin</a>, <a href="https://publications.waset.org/abstracts/search?q=darknet" title=" darknet"> darknet</a>, <a href="https://publications.waset.org/abstracts/search?q=drugs" title=" drugs"> drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=policy" title=" policy "> policy </a> </p> <a href="https://publications.waset.org/abstracts/32113/drugs-silk-road-bitcoins" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/32113.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">439</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1440</span> A Field Study of Monochromatic Light Effects on Antibody Responses to Newcastle Disease by HI Test and the Correlation with ELISA</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Seyed%20Mehrzad%20Pahlavani">Seyed Mehrzad Pahlavani</a>, <a href="https://publications.waset.org/abstracts/search?q=Mozaffar%20Haji%20Jafari%20Anaraki"> Mozaffar Haji Jafari Anaraki</a>, <a href="https://publications.waset.org/abstracts/search?q=Sayma%20Mohammadi"> Sayma Mohammadi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A total of 34700 day-old broilers were exposed to green, blue and yellow light using a light-emitting diode system for 6 weeks to investigate the effects of light wave length on antibody responses to Newcastle disease by HI test and the correlation with ELISA. 3 poultry house broiler farms with the same conditions was selected and the lightening system of each was set according to the requirement. Blood samples were taken from 20 chicks on days 1, 24 and 46 and the Newcastle virus specific antibody was titered in serum using HI an ELISA test. On day 24, the probability value of more than 0/05 was observed in HI and ELISA tests of all groups while at the end of breeding period, the average HI serum antibody titer was more in the green light than the yellow one while the blue light was not significantly different from both. At the last titration, the green light has got the highest titer of Newcastle antibodies. There were no significant differences of Newcastle antibody titers between all groups and ages in broiler pullets in ELISA. According to the sampling and analysis of HI and ELISA serum tests, there were no significant relationships between all broiler pullets breeding in green, blue and yellow light on days 24 and 46 and the P-value was more than 0/05. It is suggested that the monochromatic light is effective on broilers immunity against Newcastle disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=monochromatic%20light" title="monochromatic light">monochromatic light</a>, <a href="https://publications.waset.org/abstracts/search?q=Newcastle%20disease" title=" Newcastle disease"> Newcastle disease</a>, <a href="https://publications.waset.org/abstracts/search?q=HI%20test" title=" HI test"> HI test</a>, <a href="https://publications.waset.org/abstracts/search?q=ELISA%20test" title=" ELISA test"> ELISA test</a> </p> <a href="https://publications.waset.org/abstracts/6039/a-field-study-of-monochromatic-light-effects-on-antibody-responses-to-newcastle-disease-by-hi-test-and-the-correlation-with-elisa" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/6039.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">657</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1439</span> Periplasmic Expression of Anti-RoxP Antibody Fragments in Escherichia Coli.</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Caspar%20S.%20Carson">Caspar S. Carson</a>, <a href="https://publications.waset.org/abstracts/search?q=Gabriel%20W.%20Prather"> Gabriel W. Prather</a>, <a href="https://publications.waset.org/abstracts/search?q=Nicholas%20E.%20Wong"> Nicholas E. Wong</a>, <a href="https://publications.waset.org/abstracts/search?q=Jeffery%20R.%20Anton"> Jeffery R. Anton</a>, <a href="https://publications.waset.org/abstracts/search?q=William%20H.%20McCoy"> William H. McCoy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cutibacterium acnes is a commensal bacterium found on human skin that has been linked to acne. C. acnes can also be an opportunistic pathogen when it infiltrates the body during surgery. This pathogen can cause dangerous infections of medical implants, such as shoulder replacements, leading to life-threatening blood infections. Compounding this issue, C. acnes resistance to many antibiotics has become an increasing problem worldwide, creating a need for special forms of treatment. C. acnes expresses the protein RoxP, and it requires this protein to colonize human skin. Though this protein is required for C. acnes skin colonization, its function is not yet understood. Inhibition of RoxP function might be an effective treatment for C. acnes infections. To develop such reagents, the McCoy Laboratory generated four unique anti-RoxP antibodies. Preliminary studies in the McCoy Lab have established that each antibody binds a distinct site on RoxP. To assess the potential of these antibodies as therapeutics, it is necessary to specifically characterize these antibody epitopes and evaluate them in assays that assess their ability to inhibit RoxP-dependent C. acnes growth. To provide material for these studies, an antibody expression construct, Fv-clasp(v2), was adapted to encode anti-RoxP antibody sequences. The author hypothesizes that this expression strategy can produce sufficient amounts of >95% pure antibody fragments for further characterization of these antibodies. Four anti-RoxP Fv-clasp(v2) expression constructs (pET vector-based) were transformed into E. coli BL21-Gold(DE3) cells and a small-scale expression and purification trial was performed for each construct to evaluate anti-RoxP Fv-clasp(v2) yield and purity. Successful expression and purification of these antibody constructs will allow for their use in structural studies, such as protein crystallography and cryogenic electron microscopy. Such studies would help to define the antibody binding sites on RoxP, which could then be leveraged in the development of certain methods to treat C. acnes infection through RoxP inhibition. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=structural%20biology" title="structural biology">structural biology</a>, <a href="https://publications.waset.org/abstracts/search?q=protein%20expression" title=" protein expression"> protein expression</a>, <a href="https://publications.waset.org/abstracts/search?q=infectious%20disease" title=" infectious disease"> infectious disease</a>, <a href="https://publications.waset.org/abstracts/search?q=antibody" title=" antibody"> antibody</a>, <a href="https://publications.waset.org/abstracts/search?q=therapeutics" title=" therapeutics"> therapeutics</a>, <a href="https://publications.waset.org/abstracts/search?q=E.%20coli" title=" E. coli"> E. coli</a> </p> <a href="https://publications.waset.org/abstracts/171298/periplasmic-expression-of-anti-roxp-antibody-fragments-in-escherichia-coli" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/171298.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">60</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1438</span> Drug Use Knowledge and Antimicrobial Drug Use Behavior</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Pimporn%20Thongmuang">Pimporn Thongmuang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The import value of antimicrobial drugs reached approximately fifteen million Baht in 2010, considered as the highest import value of all modern drugs, and this value is rising every year. Antimicrobials are considered the hazardous drugs by the Ministry of Public Health. This research was conducted in order to investigate the past knowledge of drug use and Antimicrobial drug use behavior. A total of 757 students were selected as the samples out of a population of 1,800 students. This selected students had the experience of Antimicrobial drugs use a year ago. A questionnaire was utilized in this research. The findings put on the view that knowledge gained by the students about proper use of antimicrobial drugs was not brought into practice. This suggests that the education procedure regarding drug use needs adjustment. And therefore the findings of this research are expected to be utilized as guidelines for educating people about the proper use of antimicrobial drugs. At a broader perspective, correct drug use behavior of the public may potentially reduce drug cost of the Ministry of Public Health of Thailand. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=drug%20use%20knowledge" title="drug use knowledge">drug use knowledge</a>, <a href="https://publications.waset.org/abstracts/search?q=antimicrobial%20drugs" title=" antimicrobial drugs"> antimicrobial drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20use%20behavior" title=" drug use behavior"> drug use behavior</a>, <a href="https://publications.waset.org/abstracts/search?q=drug" title=" drug"> drug</a> </p> <a href="https://publications.waset.org/abstracts/3900/drug-use-knowledge-and-antimicrobial-drug-use-behavior" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/3900.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">280</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1437</span> Targeting Trypanosoma brucei Using Antibody Drug Conjugates against the Transferrin Receptor</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Camilla%20Trevor">Camilla Trevor</a>, <a href="https://publications.waset.org/abstracts/search?q=Matthew%20K.%20Higgins"> Matthew K. Higgins</a>, <a href="https://publications.waset.org/abstracts/search?q=Andrea%20Gonzalez-Munoz"> Andrea Gonzalez-Munoz</a>, <a href="https://publications.waset.org/abstracts/search?q=Mark%20Carrington"> Mark Carrington</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Trypanosomiasis is a devastating disease affecting both humans and livestock in sub-Saharan Africa. The diseases are caused by infection with African trypanosomes, protozoa transmitted by tsetse flies. Treatment currently relies on the use of chemotherapeutics with ghastly side effects. Here, we describe the development of effective antibody-drug conjugates that target the T. brucei transferrin receptor. The receptor is essential for trypanosome growth in a mammalian host but there are approximately 12 variants of the transferrin receptor in the genome. Two of the most divergent variants were used to generate recombinant monoclonal immunoglobulin G using phage display and we identified cross-reactive antibodies that bind both variants using phage ELISA, fluorescence resonance energy transfer assays and surface plasmon resonance. Fluorescent antibodies were used to demonstrate uptake into trypanosomes in culture. Toxin-conjugated antibodies were effective at killing trypanosomes at sub-nanomolar concentrations. The approach of using antibody-drug conjugates has proven highly effective. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=antibody-drug%20conjugates" title="antibody-drug conjugates">antibody-drug conjugates</a>, <a href="https://publications.waset.org/abstracts/search?q=phage%20display" title=" phage display"> phage display</a>, <a href="https://publications.waset.org/abstracts/search?q=transferrin%20receptor" title=" transferrin receptor"> transferrin receptor</a>, <a href="https://publications.waset.org/abstracts/search?q=trypanosomes" title=" trypanosomes"> trypanosomes</a> </p> <a href="https://publications.waset.org/abstracts/99250/targeting-trypanosoma-brucei-using-antibody-drug-conjugates-against-the-transferrin-receptor" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/99250.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">155</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1436</span> SEM Detection of Folate Receptor in a Murine Breast Cancer Model Using Secondary Antibody-Conjugated, Gold-Coated Magnetite Nanoparticles</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yasser%20A.%20Ahmed">Yasser A. Ahmed</a>, <a href="https://publications.waset.org/abstracts/search?q=Juleen%20M%20Dickson"> Juleen M Dickson</a>, <a href="https://publications.waset.org/abstracts/search?q=Evan%20S.%20Krystofiak"> Evan S. Krystofiak</a>, <a href="https://publications.waset.org/abstracts/search?q=Julie%20A.%20Oliver"> Julie A. Oliver</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cancer cells urgently need folate to support their rapid division. Folate receptors (FR) are over-expressed on a wide range of tumor cells, including breast cancer cells. FR are distributed over the entire surface of cancer cells, but are polarized to the apical surface of normal cells. Targeting of cancer cells using specific surface molecules such as folate receptors may be one of the strategies used to kill cancer cells without hurting the neighing normal cells. The aim of the current study was to try a method of SEM detecting FR in a murine breast cancer cell model (4T1 cells) using secondary antibody conjugated to gold or gold-coated magnetite nanoparticles. 4T1 cells were suspended in RPMI medium witth FR antibody and incubated with secondary antibody for fluorescence microscopy. The cells were cultured on 30mm Thermanox coverslips for 18 hours, labeled with FR antibody then incubated with secondary antibody conjugated to gold or gold-coated magnetite nanoparticles and processed to scanning electron microscopy (SEM) analysis. The fluorescence microscopy study showed strong punctate FR expression on 4T1 cell membrane. With SEM, the labeling with gold or gold-coated magnetite conjugates showed a similar pattern. Specific labeling occurred in nanoparticle clusters, which are clearly visualized in backscattered electron images. The 4T1 tumor cell model may be useful for the development of FR-targeted tumor therapy using gold-coated magnetite nano-particles. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer%20cell" title="cancer cell">cancer cell</a>, <a href="https://publications.waset.org/abstracts/search?q=nanoparticles" title=" nanoparticles"> nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=cell%20culture" title=" cell culture"> cell culture</a>, <a href="https://publications.waset.org/abstracts/search?q=SEM" title=" SEM"> SEM</a> </p> <a href="https://publications.waset.org/abstracts/17858/sem-detection-of-folate-receptor-in-a-murine-breast-cancer-model-using-secondary-antibody-conjugated-gold-coated-magnetite-nanoparticles" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/17858.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">734</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1435</span> First Experimental Evidence on Feasibility of Molecular Magnetic Particle Imaging of Tumor Marker Alpha-1-Fetoprotein Using Antibody Conjugated Nanoparticles</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kolja%20Them">Kolja Them</a>, <a href="https://publications.waset.org/abstracts/search?q=Priyal%20Chikhaliwala"> Priyal Chikhaliwala</a>, <a href="https://publications.waset.org/abstracts/search?q=Sudeshna%20Chandra"> Sudeshna Chandra</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: The purpose of this work is to examine possibilities for noninvasive imaging and identification of tumor markers for cancer diagnosis. The proposed method uses antibody conjugated iron oxide nanoparticles and multicolor Magnetic Particle Imaging (mMPI). The method has the potential for radiation exposure free real-time estimation of local tumor marker concentrations in vivo. In this study, the method is applied to human Alpha-1-Fetoprotein. Materials and Methods: As tracer material AFP antibody-conjugated Dendrimer-Fe3O4 nanoparticles were used. The nanoparticle bioconjugates were then incubated with bovine serum albumin (BSA) to block any possible nonspecific binding sites. Parts of the resulting solution were then incubated with AFP antigen. MPI measurements were done using the preclinical MPI scanner (Bruker Biospin MRI GmbH) and the multicolor method was used for image reconstruction. Results: In multicolor MPI images the nanoparticles incubated only with BSA were clearly distinguished from nanoparticles incubated with BSA and AFP antigens. Conclusion: Tomographic imaging of human tumor marker Alpha-1-Fetoprotein is possible using AFP antibody conjugated iron oxide nanoparticles in presence of BSA. This opens interesting perspectives for cancer diagnosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=noninvasive%20imaging" title="noninvasive imaging">noninvasive imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20antigens" title=" tumor antigens"> tumor antigens</a>, <a href="https://publications.waset.org/abstracts/search?q=antibody%20conjugated%20iron%20oxide%20nanoparticles" title=" antibody conjugated iron oxide nanoparticles"> antibody conjugated iron oxide nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=multicolor%20magnetic%20particle%20imaging" title=" multicolor magnetic particle imaging"> multicolor magnetic particle imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20diagnosis" title=" cancer diagnosis"> cancer diagnosis</a> </p> <a href="https://publications.waset.org/abstracts/73134/first-experimental-evidence-on-feasibility-of-molecular-magnetic-particle-imaging-of-tumor-marker-alpha-1-fetoprotein-using-antibody-conjugated-nanoparticles" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/73134.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">303</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1434</span> Atherosclerotic Plagues and Immune Microenvironment: From Lipid-Lowering to Anti-inflammatory and Immunomodulatory Drug Approaches in Cardiovascular Diseases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Husham%20Bayazed">Husham Bayazed</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A growing number of studies indicate that atherosclerotic coronary artery disease (CAD) has a complex pathogenesis that extends beyond cholesterol intimal infiltration. The atherosclerosis process may involve an immune micro-environmental condition driven by local activation of the adaptive and innate immunity arrays, resulting in the formation of atherosclerotic plaques. Therefore, despite the wide usage of lipid-lowering agents, these devastating coronary diseases are not averted either at primary or secondary prevention levels. Many trials have recently shown an interest in the immune targeting of the inflammatory process of atherosclerotic plaques, with the promised improvement in atherosclerotic cardiovascular disease outcomes. This recently includes the immune-modulatory drug “Canakinumab” as an anti-interleukin-1 beta monoclonal antibody in addition to "Colchicine,” which's established as a broad-effect drug in the management of other inflammatory conditions. Recent trials and studies highlight the importance of inflammation and immune reactions in the pathogenesis of atherosclerosis and plaque formation. This provides an insight to discuss and extend the therapies from old lipid-lowering drugs (statins) to anti-inflammatory drugs (colchicine) and new targeted immune-modulatory therapies like inhibitors of IL-1 beta (canakinumab) currently under investigation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=atherosclerotic%20plagues" title="atherosclerotic plagues">atherosclerotic plagues</a>, <a href="https://publications.waset.org/abstracts/search?q=immune%20microenvironment" title=" immune microenvironment"> immune microenvironment</a>, <a href="https://publications.waset.org/abstracts/search?q=lipid-lowering%20agents" title=" lipid-lowering agents"> lipid-lowering agents</a>, <a href="https://publications.waset.org/abstracts/search?q=and%20immunomodulatory%20drugs" title=" and immunomodulatory drugs"> and immunomodulatory drugs</a> </p> <a href="https://publications.waset.org/abstracts/178083/atherosclerotic-plagues-and-immune-microenvironment-from-lipid-lowering-to-anti-inflammatory-and-immunomodulatory-drug-approaches-in-cardiovascular-diseases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/178083.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">69</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1433</span> Deciphering the Gut Microbiome's Role in Early-Life Immune Development</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Xia%20Huo">Xia Huo</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Children are more vulnerable to environmental toxicants compared to adults, and their developing immune system is among the most sensitive targets regarding toxicity of environmental toxicants. Studies have found that exposure to environmental toxicants is associated with impaired immune function in children, but only a few studies have focused on the relationship between environmental toxicant exposure and vaccine antibody potency and immunoglobulin (Ig) levels in children. These studies investigated the associations of exposure to polychlorinated biphenyls (PCBs), perfluorinated compounds (PFCs), heavy metals (Pb, Cd, As, Hg) and PM2.5 with the serum-specific antibody concentrations and Ig levels against different vaccines, such as anti-Hib, tetanus, diphtheria toxoid, and analyze the possible mechanisms underlying exposure-related alterations of antibody titers and Ig levels against different vaccines. Results suggest that exposure to these toxicants is generally associated with decreased potency of antibodies produced from childhood immunizations and an overall deficiency in the protection the vaccines provide. Toxicant exposure is associated with vaccination failure and decreased antibody titers, and increased risk of immune-related diseases in children by altering specific immunoglobulin levels. Age, sex, nutritional status, and co-exposure may influence the effects of toxicants on the immune function in children. Epidemiological evidence suggests that exposure-induced changes to humoral immunerelated tissue/cells/molecules response to vaccines may have predominant roles in the inverse associations between antibody responsiveness to vaccines and environmental toxicants. These results help us to conduct better immunization policies for children under environmental toxicant burden. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=environmental%20toxicants" title="environmental toxicants">environmental toxicants</a>, <a href="https://publications.waset.org/abstracts/search?q=immunotoxicity" title=" immunotoxicity"> immunotoxicity</a>, <a href="https://publications.waset.org/abstracts/search?q=vaccination" title=" vaccination"> vaccination</a>, <a href="https://publications.waset.org/abstracts/search?q=antibodies" title=" antibodies"> antibodies</a>, <a href="https://publications.waset.org/abstracts/search?q=children%27s%20health" title=" children's health"> children's health</a> </p> <a href="https://publications.waset.org/abstracts/184614/deciphering-the-gut-microbiomes-role-in-early-life-immune-development" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/184614.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">59</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1432</span> Role of Biotechnology on Pharmaceutical Inventions: An Analysis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=E.%20Prema">E. Prema</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Biotechnology is a study relating to the practical application of living beings in different fields. Generally, it is a study with regard to living organisms in the industrial utilization. It is the technology, which uses living organisms or its parts for specific commercial use. Modification and application of living beings for different practical purposes is possible through biotechnology. Furthermore, today biotechnology is being used in different fields for better results. It is worthwhile to note here that biotechnology is one of the most innovative and intensive industries. It has used the genetically based characteristics in microorganisms, plants and animals to create drugs and to develop drug therapies, which may prevent, cure or alleviate disease and their symptoms. Drugs are basically chemicals and while patenting drugs, the conditions of patentability of chemicals and the types that can be patented are equally applicable to drugs also. Nowadays, the role of biotechnology for manufacturing drugs has assumed much importance because of intellectual property rights. By way using biotechnology, most of the pharmaceutical inventions are getting protection for the period of 20 years as per the Patents Act, 1970 as amended in 2005. There is no doubt that biotechnology is serving the public at large with regard manufacturing drugs and helping the needy people on time. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biotechnology" title="biotechnology">biotechnology</a>, <a href="https://publications.waset.org/abstracts/search?q=drugs" title=" drugs"> drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=intellectual%20property%20rights" title=" intellectual property rights"> intellectual property rights</a>, <a href="https://publications.waset.org/abstracts/search?q=patents" title=" patents "> patents </a> </p> <a href="https://publications.waset.org/abstracts/24341/role-of-biotechnology-on-pharmaceutical-inventions-an-analysis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/24341.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">454</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1431</span> Development of Gold Nanoparticles-Antibody System for the Selective Photothermal Destruction of Multidrug Resistant Bacteria</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Teodora%20Mocan">Teodora Mocan</a>, <a href="https://publications.waset.org/abstracts/search?q=Lucian%20Mocan"> Lucian Mocan</a>, <a href="https://publications.waset.org/abstracts/search?q=Cornel%20Iancu"> Cornel Iancu</a>, <a href="https://publications.waset.org/abstracts/search?q=Flaviu%20A.%20Tabaran"> Flaviu A. Tabaran</a>, <a href="https://publications.waset.org/abstracts/search?q=Bartos%20Dana"> Bartos Dana</a>, <a href="https://publications.waset.org/abstracts/search?q=Matea%20Cristian"> Matea Cristian</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Antimicrobial resistance, which threatens the efficacy of the existing antibiotics represents a worldwide public health issue. At the current time, vancomycin is the only responsive treatment although has significant cytotoxicity, is partially effective and it is poorly retained by infected tissues. From a clinical point of view, attractive alternative approaches for treating such Meticillin-Resistant Staphylococcus Aureus (MRSA) strains would be using agents that cause physical damage to the bacteria. Modular nanopharmaceuticals systems are being designed to address all of these multifunctional capabilities for the ideal bacterial treatment, with the ability to mix and match appropriate functions. Here we present a novel method of selective laser photothermal ablation of MRSA bacteria mediated by gold nanoparticles bound to PBP antibody against PBP protein located on the MRSA surface. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=MRSA" title="MRSA">MRSA</a>, <a href="https://publications.waset.org/abstracts/search?q=laser" title=" laser"> laser</a>, <a href="https://publications.waset.org/abstracts/search?q=nanoparticle" title=" nanoparticle"> nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=antibody" title=" antibody"> antibody</a> </p> <a href="https://publications.waset.org/abstracts/84089/development-of-gold-nanoparticles-antibody-system-for-the-selective-photothermal-destruction-of-multidrug-resistant-bacteria" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/84089.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">281</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1430</span> In silico and in vitro Investigation of the Role of Acinetobacter baumannii in the Pathogenesis of Multiple Sclerosis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kieren%20Luellman">Kieren Luellman</a>, <a href="https://publications.waset.org/abstracts/search?q=Makenzi%20Rockwell"> Makenzi Rockwell</a>, <a href="https://publications.waset.org/abstracts/search?q=Eduardo%20Callegari"> Eduardo Callegari</a>, <a href="https://publications.waset.org/abstracts/search?q=Nichole%20Haag"> Nichole Haag</a>, <a href="https://publications.waset.org/abstracts/search?q=Chun%20Wu"> Chun Wu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Multiple sclerosis (MS) is an autoimmune disorder that damages the myelin sheath of neurons in the central nervous system. The presence of Acinetobacter bacteria and anti-Acinetobacter antibodies in MS patients has led to the hypothesis that the bacteria may contribute to MS pathogenesis. In this study, the protein sequences of Acinetobacter baumannii were compared to five peptides from three mammalian myelin proteins, i.e., Proteolipid Protein (PLP): PLP 139-151, PLP 178-191, Myelin Basic Protein (MBP): MBP 84-104 and Myelin Oligodendrocyte Glycoprotein (MOG): MOG 35-55 and MOG 92-106 respectively, known to induce experimental autoimmune encephalomyelitis (EAE), a condition similar to MS. We found 11 hits (i.e., with five or more amino acid sequence similarity) in Acinetobacter baumannii, which are identical or similar to PLP139-151, 32 hits to PLP178-191, 35 to MBP 84-104, 41 hits to MOG 35-55 and 26 hits to MOG92-106. In addition, Western blotting was used to assess possible interaction between the bacterial proteins and human anti-MBP, anti-MOG, and anti-PLP antibodies produced in rabbits, corresponding to MBP 84-104, MOG 35-55, and PLP 139-151, respectively. We found that both human Polyclonal anti-MOG antibody and anti-PLP antibody recognized a protein or more proteins of the same molecular mass of around 25 kDa. in Acinetobacter baumannii. The results suggested that this/these protein(s) might potentially serve as antigen(s) to induce anti-MOG antibody and anti-PLP antibody production in mammalian B cells. The proteomic study identified 433 hits, among which the sequence of Acinetobacter baumannii protein 491 subunit A matches a previously published enzyme Acinetobacter 3-Oxoadipate CoA-Transferase, in which a fragment of its peptide was observed to recognize MS patient serum via ELISA method. Our findings might pave the road to understanding one of the pathogenesis mechanisms of MS. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=multiple%20sclerosis" title="multiple sclerosis">multiple sclerosis</a>, <a href="https://publications.waset.org/abstracts/search?q=pathogenesis" title=" pathogenesis"> pathogenesis</a>, <a href="https://publications.waset.org/abstracts/search?q=Acinetobacter%20baumannii" title=" Acinetobacter baumannii"> Acinetobacter baumannii</a>, <a href="https://publications.waset.org/abstracts/search?q=antibody%20recognition" title=" antibody recognition"> antibody recognition</a> </p> <a href="https://publications.waset.org/abstracts/165107/in-silico-and-in-vitro-investigation-of-the-role-of-acinetobacter-baumannii-in-the-pathogenesis-of-multiple-sclerosis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/165107.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">121</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1429</span> Neutralizing Antibody Response against Inactivated FMDV Type O/IRN/2010 Vaccine by Electron Beam in BALB/C Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=F.%20Motamedi%20Sedeh">F. Motamedi Sedeh</a>, <a href="https://publications.waset.org/abstracts/search?q=Sh.%20Chahardoli"> Sh. Chahardoli</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Mahravani"> H. Mahravani</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20Harzandi"> N. Harzandi</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Sotoodeh"> M. Sotoodeh</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20K.%20Shafaei"> S. K. Shafaei </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Foot-and-mouth disease virus (FMDV) is the most economically important disease of livestock. The aim of the study is inactivation of FMD virus type O/IRN/2010 by electron beam without antigenic changes as electron radio vaccine. The BALB/C mice were divided into three groups, each group containing five mice. Three groups of mice were inoculated with conventional vaccine and electron beam irradiated vaccine FMDV type O/IRN/2010 subcutaneously three weeks interval, the final group as negative control. The sera were separated from the blood samples of mice 14 days after last vaccination and tested for the presence of antibodies against FMDV type O/IRN/2010 by serum neutralization test. The Serum Neutralization Test (SNT) was carried out and antibody titration was calculated according to the Kraber protocol. The results of the SNT in three groups of mice showed the titration of neutralizing antibody in the vaccinated mice groups; electron radio vaccine and conventional vaccine were significantly higher than negative control group (P<0.05). Therefore, the radio vaccine is a good candidate to immunize animals against FMDV type O/IRN/2010. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=FMDV%20type%20O%2FIRN%2F2010" title="FMDV type O/IRN/2010">FMDV type O/IRN/2010</a>, <a href="https://publications.waset.org/abstracts/search?q=neutralizing%20antibody%20response" title=" neutralizing antibody response"> neutralizing antibody response</a>, <a href="https://publications.waset.org/abstracts/search?q=electron%20beam" title=" electron beam"> electron beam</a>, <a href="https://publications.waset.org/abstracts/search?q=radio%20vaccine" title=" radio vaccine"> radio vaccine</a> </p> <a href="https://publications.waset.org/abstracts/11949/neutralizing-antibody-response-against-inactivated-fmdv-type-oirn2010-vaccine-by-electron-beam-in-balbc-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/11949.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">318</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1428</span> Occurrence of Illicit Drugs in Aqueous Environment and Removal Efficiency of Wastewater Treatment Plants</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Meena%20K.%20Yadav">Meena K. Yadav</a>, <a href="https://publications.waset.org/abstracts/search?q=Rupak%20Aryal"> Rupak Aryal</a>, <a href="https://publications.waset.org/abstracts/search?q=Michael%20D.%20%20Short"> Michael D. Short</a>, <a href="https://publications.waset.org/abstracts/search?q=Ben%20Van%20Den%20Akker"> Ben Van Den Akker</a>, <a href="https://publications.waset.org/abstracts/search?q=Christopher%20P.%20Saint"> Christopher P. Saint</a>, <a href="https://publications.waset.org/abstracts/search?q=Cobus%20Gerber"> Cobus Gerber</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Illicit drugs are considered as emerging contaminants of concern that have become an interesting issue for the scientific community from last few years due to their existence in the water environment. A number of the literature has revealed their occurrence in the environment. This is mainly due to the fact that some drugs are partially removed during wastewater treatment processes, and remaining being able to enter the environment and contaminate surface and groundwater and subsequently, drinking water. Therefore, this paper evaluates the occurrence of key illicit drugs in wastewater (influent and effluent) samples in 4 wastewater treatment plants across Adelaide, South Australia over a 1 year period. This paper also compares the efficiency of wastewater treatment plants adopting different technologies in the removal of selected illicit drugs, especially in the context of which technology has higher removal rates. The influent and effluent samples were analysed using Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS). The levels of drugs detected were in the range of mg/L – ng/L in effluent samples; thus emphasising the influence on water quality of receiving water bodies and the significance of removal efficiency of WWTPs(Wastewater Treatment Plants). The results show that the drugs responded differently in the removal depending on the treatment processes used by the WWTPs. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=illicit%20drugs" title="illicit drugs">illicit drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=removal%20efficiency" title=" removal efficiency"> removal efficiency</a>, <a href="https://publications.waset.org/abstracts/search?q=treatment%20technology" title=" treatment technology"> treatment technology</a>, <a href="https://publications.waset.org/abstracts/search?q=wastewater" title=" wastewater"> wastewater</a> </p> <a href="https://publications.waset.org/abstracts/73289/occurrence-of-illicit-drugs-in-aqueous-environment-and-removal-efficiency-of-wastewater-treatment-plants" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/73289.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">262</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1427</span> The Contribution of the Lomé Charter to Combating Drugs Trafficking at Sea: Nigerian and South African Legal Perspectives</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Obinna%20Emmanuel%20Nkomadu">Obinna Emmanuel Nkomadu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The sea attracts many criminal activities including drug trafficking. The illicit traffic in narcotic drugs and psychotropic substances by sea poses a serious threat to maritime security globally. The seizure of drugs, particularly, on the African continent is on the raise. In terms of Southern Africa, South Africa is a major transit point for Latin American drugs and South Africa is the largest market for illicit drugs entering the Southern African region. Nigeria and South Africa have taken a number of steps to address this scourge, but, despite those steps, drugs trafficking at sea continues. For that reason and to combat a number of other threats to maritime security around the continent, a substantial number of AU members in 2016 adopted the African Charter on Maritime Security and Safety and Development in Africa (“the Charter”). However, the Charter is yet to come into force due to the number of States required to accede or ratify the Charter. This paper set out the pre-existing international instruments on drugs, to ascertain the domestic laws of Nigeria and South Africa relating to drugs with the relevant provisions of the Lomé Charter in order to establish whether any legal steps are required to ensure that Nigeria and South Africa comply with its obligations under the Charter. Indeed, should Nigeria and South Africa decide to ratify it and should it come into force, both States must cooperate with other relevant States in establishing policies, as well as a regional and continental institutions, and ensure the implementation of such policies. The paper urged the States to urgently ratify the Charter as it is a step in the right direction in the prevention and repression of drugs trafficking on the African maritime domain. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cooperation%20against%20drugs%20trafficking%20at%20sea" title="cooperation against drugs trafficking at sea">cooperation against drugs trafficking at sea</a>, <a href="https://publications.waset.org/abstracts/search?q=Lom%C3%A9%20Charter" title=" Lomé Charter"> Lomé Charter</a>, <a href="https://publications.waset.org/abstracts/search?q=maritime%20security" title=" maritime security"> maritime security</a>, <a href="https://publications.waset.org/abstracts/search?q=Nigerian%20and%20South%20Africa%20legislation%20on%20drugs" title=" Nigerian and South Africa legislation on drugs"> Nigerian and South Africa legislation on drugs</a> </p> <a href="https://publications.waset.org/abstracts/158896/the-contribution-of-the-lome-charter-to-combating-drugs-trafficking-at-sea-nigerian-and-south-african-legal-perspectives" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/158896.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">97</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1426</span> Investigation of Chronic Drug Use Due to Chronic Diseases in Patients Admitted to Emergency Department</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Behcet%20Al">Behcet Al</a>, <a href="https://publications.waset.org/abstracts/search?q=%C5%9Eener%20Cindoruk"> Şener Cindoruk</a>, <a href="https://publications.waset.org/abstracts/search?q=Suat%20Zengin"> Suat Zengin</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehmet%20Murat%20Oktay"> Mehmet Murat Oktay</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehmet%20Mustafa%20Sunar"> Mehmet Mustafa Sunar</a>, <a href="https://publications.waset.org/abstracts/search?q=Hatice%20Eroglu"> Hatice Eroglu</a>, <a href="https://publications.waset.org/abstracts/search?q=Cuma%20Yildirim"> Cuma Yildirim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objective: In present study we aimed to investigate the chronic drug use due to chronic diseases in patients admitted to emergency department. Materials-Methods: 144 patients who applied to emergency department (ED) of medicine school of Gaziantep University between June 2013 and September 2013 with chronic diseases and use chronic drugs were included. Information about drugs used by patients were recorded. Results: Of patients, half were male, half were female, and the mean age was 58 years. The first three common diseases were diabetes mellitus, hypertension and coronary artery diseases. Of patients, %79.2 knew their illness. Fifty patients began to use drug within three months, 36 patient began to use within the last one year. While 42 patients brought all of their drugs with themselves, 17 patients brought along a portion of drugs. While three patients stopped their medication completely, 125 patients received medication on a regular basis. Fifty-two patient described the drugs with names, 13 patients described with their colors, 3 patients described by grammes, 45 patients described with the size of the tablet and 13 patients could not describe the drugs. Ninety-two patients explained which kind of drugs were used for each diseases, 17 patient explained partly, and 35 patients had no idea. Hundred patients received medication by themselves, 44 patients medications were giving by their relatives and med carers. Of medications, 140 were written by doctors directly, three medication were given by pharmacist; and one patient bought the drug by himself. For 11 patients the drugs were not harmonious to their diseases. Fifty-one patients admitted to the ED two times within last week, and 73 admitted two times within last month. Conclusion: The majority of patients with chronic diseases and use chronic drugs know their diseases and use the drugs in order, but do not have enough information about their medication. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20disease" title="chronic disease">chronic disease</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20use" title=" drug use"> drug use</a>, <a href="https://publications.waset.org/abstracts/search?q=emergency%20department" title=" emergency department"> emergency department</a>, <a href="https://publications.waset.org/abstracts/search?q=medication" title=" medication"> medication</a> </p> <a href="https://publications.waset.org/abstracts/12353/investigation-of-chronic-drug-use-due-to-chronic-diseases-in-patients-admitted-to-emergency-department" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/12353.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">463</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1425</span> DNA Hypomethylating Agents Induced Histone Acetylation Changes in Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sridhar%20A.%20Malkaram">Sridhar A. Malkaram</a>, <a href="https://publications.waset.org/abstracts/search?q=Tamer%20E.%20Fandy"> Tamer E. Fandy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: 5-Azacytidine (5AC) and decitabine (DC) are DNA hypomethylating agents. We recently demonstrated that both drugs increase the enzymatic activity of the histone deacetylase enzyme SIRT6. Accordingly, we are comparing the changes H3K9 acetylation changes in the whole genome induced by both drugs using leukemia cells. Description of Methods & Materials: Mononuclear cells from the bone marrow of six de-identified naive acute myeloid leukemia (AML) patients were cultured with either 500 nM of DC or 5AC for 72 h followed by ChIP-Seq analysis using a ChIP-validated acetylated-H3K9 (H3K9ac) antibody. Chip-Seq libraries were prepared from treated and untreated cells using SMARTer ThruPLEX DNA- seq kit (Takara Bio, USA) according to the manufacturer’s instructions. Libraries were purified and size-selected with AMPure XP beads at 1:1 (v/v) ratio. All libraries were pooled prior to sequencing on an Illumina HiSeq 1500. The dual-indexed single-read Rapid Run was performed with 1x120 cycles at 5 pM final concentration of the library pool. Sequence reads with average Phred quality < 20, with length < 35bp, PCR duplicates, and those aligning to blacklisted regions of the genome were filtered out using Trim Galore v0.4.4 and cutadapt v1.18. Reads were aligned to the reference human genome (hg38) using Bowtie v2.3.4.1 in end-to-end alignment mode. H3K9ac enriched (peak) regions were identified using diffReps v1.55.4 software using input samples for background correction. The statistical significance of differential peak counts was assessed using a negative binomial test using all individuals as replicates. Data & Results: The data from the six patients showed significant (Padj<0.05) acetylation changes at 925 loci after 5AC treatment versus 182 loci after DC treatment. Both drugs induced H3K9 acetylation changes at different chromosomal regions, including promoters, coding exons, introns, and distal intergenic regions. Ten common genes showed H3K9 acetylation changes by both drugs. Approximately 84% of the genes showed an H3K9 acetylation decrease by 5AC versus 54% only by DC. Figures 1 and 2 show the heatmaps for the top 100 genes and the 99 genes showing H3K9 acetylation decrease after 5AC treatment and DC treatment, respectively. Conclusion: Despite the similarity in hypomethylating activity and chemical structure, the effect of both drugs on H3K9 acetylation change was significantly different. More changes in H3K9 acetylation were observed after 5 AC treatments compared to DC. The impact of these changes on gene expression and the clinical efficacy of these drugs requires further investigation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=DNA%20methylation" title="DNA methylation">DNA methylation</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia" title=" leukemia"> leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=decitabine" title=" decitabine"> decitabine</a>, <a href="https://publications.waset.org/abstracts/search?q=5-Azacytidine" title=" 5-Azacytidine"> 5-Azacytidine</a>, <a href="https://publications.waset.org/abstracts/search?q=epigenetics" title=" epigenetics"> epigenetics</a> </p> <a href="https://publications.waset.org/abstracts/143615/dna-hypomethylating-agents-induced-histone-acetylation-changes-in-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/143615.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">149</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1424</span> Synthesis of New Anti-Tuberculosis Drugs</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20S.%20Deshpande">M. S. Deshpande</a>, <a href="https://publications.waset.org/abstracts/search?q=Snehal%20D.%20Bomble"> Snehal D. Bomble</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tuberculosis (TB) is a deadly contagious disease that is caused by a bacterium called Mycobacterium tuberculosis. More than sixty years ago, the introduction of the first anti-TB drugs for the treatment of TB (streptomycin (STR), p-aminosalcylic acid (PAS), isoniazid (INH), and then later ethambutol (EMB) and rifampicin (RIF)) gave optimism to the medical community, and it was believed that the disease would be completely eradicated soon. Worldwide, the number of TB cases has continued to increase, but the incidence rate has decreased since 2003. Recently, highly drug-resistant forms of TB have emerged worldwide. The prolonged use of classical drugs developed a growing resistance and these drugs have gradually become less effective and incapable to meet the challenges, especially those of multi drug resistant (MDR)-TB, extensively drug resistant (XDR)-TB, and HIV-TB co-infections. There is an unmet medical need to discover newer synthetic molecules and new generation of potent drugs for the treatment of tuberculosis which will shorten the time of treatment, be potent and safe while effective facing resistant strains and non-replicative, latent forms, reduce adverse side effect and not interfere in the antiretroviral therapy. This paper attempts to bring out the review of anti-TB drugs, and presents a novel method of synthesizing new anti-tuberculosis drugs and potential compounds to overcome the bacterial resistance and combat the re-emergence of tuberculosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=tuberculosis" title="tuberculosis">tuberculosis</a>, <a href="https://publications.waset.org/abstracts/search?q=mycobacterium" title=" mycobacterium"> mycobacterium</a>, <a href="https://publications.waset.org/abstracts/search?q=multi-drug%20resistant%20%28MDR%29-TB" title=" multi-drug resistant (MDR)-TB"> multi-drug resistant (MDR)-TB</a>, <a href="https://publications.waset.org/abstracts/search?q=extensively%20drug%20resistant%20%28XDR%29-TB" title=" extensively drug resistant (XDR)-TB"> extensively drug resistant (XDR)-TB</a> </p> <a href="https://publications.waset.org/abstracts/1484/synthesis-of-new-anti-tuberculosis-drugs" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/1484.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">380</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1423</span> Nanoparticle-Based Histidine-Rich Protein-2 Assay for the Detection of the Malaria Parasite Plasmodium Falciparum </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yagahira%20E.%20Castro-Sesquen">Yagahira E. Castro-Sesquen</a>, <a href="https://publications.waset.org/abstracts/search?q=Chloe%20Kim"> Chloe Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=Robert%20H.%20Gilman"> Robert H. Gilman</a>, <a href="https://publications.waset.org/abstracts/search?q=David%20J.%20Sullivan"> David J. Sullivan</a>, <a href="https://publications.waset.org/abstracts/search?q=Peter%20C.%20Searson"> Peter C. Searson </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Diagnosis of severe malaria is particularly important in highly endemic regions since most patients are positive for parasitemia and treatment differs from non-severe malaria. Diagnosis can be challenging due to the prevalence of diseases with similar symptoms. Accurate diagnosis is increasingly important to avoid overprescribing antimalarial drugs, minimize drug resistance, and minimize costs. A nanoparticle-based assay for detection and quantification of Plasmodium falciparum histidine-rich protein 2 (HRP2) in urine and serum is reported. The assay uses magnetic beads conjugated with anti-HRP2 antibody for protein capture and concentration, and antibody-conjugated quantum dots for optical detection. Western Blot analysis demonstrated that magnetic beads allows the concentration of HRP2 protein in urine by 20-fold. The concentration effect was achieved because large volume of urine can be incubated with beads, and magnetic separation can be easily performed in minutes to isolate beads containing HRP2 protein. Magnetic beads and Quantum Dots 525 conjugated to anti-HRP2 antibodies allows the detection of low concentration of HRP2 protein (0.5 ng mL-1), and quantification in the range of 33 to 2,000 ng mL-1 corresponding to the range associated with non-severe to severe malaria. This assay can be easily adapted to a non-invasive point-of-care test for classification of severe malaria. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HRP2%20protein" title="HRP2 protein">HRP2 protein</a>, <a href="https://publications.waset.org/abstracts/search?q=malaria" title=" malaria"> malaria</a>, <a href="https://publications.waset.org/abstracts/search?q=magnetic%20beads" title=" magnetic beads"> magnetic beads</a>, <a href="https://publications.waset.org/abstracts/search?q=Quantum%20dots" title=" Quantum dots"> Quantum dots</a> </p> <a href="https://publications.waset.org/abstracts/40731/nanoparticle-based-histidine-rich-protein-2-assay-for-the-detection-of-the-malaria-parasite-plasmodium-falciparum" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/40731.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">333</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1422</span> Anti-Phosphorylcholine T Cell Dependent Antibody</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20M.%20Rahman">M. M. Rahman</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Liu"> A. Liu</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Frostegard"> A. Frostegard</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20Frostegard"> J. Frostegard</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The human immune system plays an essential role in cardiovascular disease (CVD) and atherosclerosis. Our earlier studies showed that major immunocompetent cells including T cells are activated by phosphorylcholine epitope. Further, we have determined for the first time in a clinical cohort that antibodies against phosphorylcholine (anti-PC) are negatively and independently associated with the development of atherosclerosis and thus a low risk of cardiovascular diseases. It is still unknown whether activated T cells play a role in anti-PC production. Here we aim to clarify the role of T cells in anti-PC production. B cell alone, or with CD3 T, CD4 T or with CD8 T cells were cultured in polystyrene plates to examine anti-PC IgM production. In addition to mixed B cell with CD3 T cell culture, B cells with CD3 T cells were also cultured in transwell co-culture plates. Further, B cells alone and mixed B cell with CD3 T cell cultures with or without anti-HLA 2 antibody were cultured for 6 days. Anti-PC IgM was detected by ELISA in independent experiments. More than 8 fold higher levels of anti-PC IgM were detected by ELISA in mixed B cell with CD3 T cell cultures in comparison to B cells alone. After the co-culture of B and CD3 T cells in transwell plates, there were no increased antibody levels indicating that B and T cells need to interact to augment anti-PC IgM production. Furthermore, anti-PC IgM was abolished by anti-HLA 2 blocking antibody in mixed B and CD3 T cells culture. In addition, the lack of increased anti-PC IgM in mixed B with CD8 T cells culture and the increased levels of anti-PC in mixed B with CD4 T cells culture support the role of helper T cell for the anti-PC IgM production. Atherosclerosis is a major cause of cardiovascular diseases, but anti-PC IgM is a protection marker for atherosclerosis development. Understanding the mechanism involved in the anti-PC IgM regulation could play an important role in strategies to raise anti-PC IgM. Studies suggest that anti-PC is T-cell independent antibody, but our study shows the major role of T cell in anti-PC IgM production. Activation of helper T cells by immunization could be a possible mechanism for raising anti-PC levels. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anti-PC" title="anti-PC">anti-PC</a>, <a href="https://publications.waset.org/abstracts/search?q=atherosclerosis" title=" atherosclerosis"> atherosclerosis</a>, <a href="https://publications.waset.org/abstracts/search?q=aardiovascular%20diseases" title=" aardiovascular diseases"> aardiovascular diseases</a>, <a href="https://publications.waset.org/abstracts/search?q=phosphorylcholine" title=" phosphorylcholine"> phosphorylcholine</a> </p> <a href="https://publications.waset.org/abstracts/33407/anti-phosphorylcholine-t-cell-dependent-antibody" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/33407.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">341</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1421</span> Ultra-Fast pH-Gradient Ion Exchange Chromatography for the Separation of Monoclonal Antibody Charge Variants</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Robert%20van%20Ling">Robert van Ling</a>, <a href="https://publications.waset.org/abstracts/search?q=Alexander%20Schwahn"> Alexander Schwahn</a>, <a href="https://publications.waset.org/abstracts/search?q=Shanhua%20Lin"> Shanhua Lin</a>, <a href="https://publications.waset.org/abstracts/search?q=Ken%20Cook"> Ken Cook</a>, <a href="https://publications.waset.org/abstracts/search?q=Frank%20Steiner"> Frank Steiner</a>, <a href="https://publications.waset.org/abstracts/search?q=Rowan%20Moore"> Rowan Moore</a>, <a href="https://publications.waset.org/abstracts/search?q=Mauro%20de%20Pra"> Mauro de Pra</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: Demonstration of fast high resolution charge variant analysis for monoclonal antibody (mAb) therapeutics within 5 minutes. Methods: Three commercially available mAbs were used for all experiments. The charge variants of therapeutic mAbs (Bevacizumab, Cetuximab, Infliximab, and Trastuzumab) are analyzed on a strong cation exchange column with a linear pH gradient separation method. The linear gradient from pH 5.6 to pH 10.2 is generated over time by running a linear pump gradient from 100% Thermo Scientific™ CX-1 pH Gradient Buffer A (pH 5.6) to 100% CX-1 pH Gradient Buffer B (pH 10.2), using the Thermo Scientific™ Vanquish™ UHPLC system. Results: The pH gradient method is generally applicable to monoclonal antibody charge variant analysis. In conjunction with state-of-the-art column and UHPLC technology, ultra fast high-resolution separations are consistently achieved in under 5 minutes for all mAbs analyzed. Conclusion: The linear pH gradient method is a platform method for mAb charge variant analysis. The linear pH gradient method can be easily optimized to improve separations and shorten cycle times. Ultra-fast charge variant separation is facilitated with UHPLC that complements, and in some instances outperforms CE approaches in terms of both resolution and throughput. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=charge%20variants" title="charge variants">charge variants</a>, <a href="https://publications.waset.org/abstracts/search?q=ion%20exchange%20chromatography" title=" ion exchange chromatography"> ion exchange chromatography</a>, <a href="https://publications.waset.org/abstracts/search?q=monoclonal%20antibody" title=" monoclonal antibody"> monoclonal antibody</a>, <a href="https://publications.waset.org/abstracts/search?q=UHPLC" title=" UHPLC"> UHPLC</a> </p> <a href="https://publications.waset.org/abstracts/63884/ultra-fast-ph-gradient-ion-exchange-chromatography-for-the-separation-of-monoclonal-antibody-charge-variants" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/63884.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">440</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=48">48</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=49">49</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=antibody%20drugs&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>